Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632306 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01632306: Clinical Trial Phase 1 study, sponsored by Eli Lilly and Company.
NCT01632306 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01632306, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.
Primary Outcome
Change in the phosphorylation level of glycogen synthase, a glycogen synthase kinase-3 beta (GSK-3beta) inhibitor, from baseline to 4 hours post-treatment on day 0 using tumor tissue and blood specimens.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG FOLFOX
- DRUG LY2090314
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Why NCT01632306 stopped before completion
NCT01632306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine is the first listed.
NCT01632306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01632306 about?
NCT01632306 is a clinical study titled "A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer". Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.
What is the current status of trial NCT01632306?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2013-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01632306?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), FOLFOX (DRUG), LY2090314 (DRUG).
Who is sponsoring clinical trial NCT01632306?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01632306's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia